Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206713 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
NCT00206713 is a Phase 3 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 264 participants.
The verdict
NCT00206713, a Phase 3 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether treatment with Leukine in patients with Crohn's disease who have previously responded to Leukine can be helped again, once they have relapsed.
Interventions
- DRUG Placebo
- DRUG Sargramostim (Leukine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206713
The ClinicalTrials.gov registry entry for NCT00206713 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00206713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206713 about?
NCT00206713 is a clinical study titled "Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim". The purpose of this study is to evaluate whether treatment with Leukine in patients with Crohn's disease who have previously responded to Leukine can be helped again, once they have relapsed.
What is the current status of trial NCT00206713?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2004-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00206713?
The interventions under investigation include: Placebo (DRUG), Sargramostim (Leukine) (DRUG).
Who is sponsoring clinical trial NCT00206713?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.